MALVERN, Pa., March 21, 2022 (World NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a medical-stage biopharmaceutical corporation targeted on exploring, building, and commercializing gene therapies to get rid of blindness diseases and establishing a vaccine to help save lives from COVID-19, today introduced the appointment of Jessica Crespo, CPA, as Main Accounting Officer and Senior Vice President, Finance. She assumed the job successful March 18, 2022.
In this position, she will be accountable for the progress and execution of the Company’s fiscal method, as effectively as all company finance, accounting, and interior and external economic reporting functions. She will provide as a member of Ocugen’s management group, reporting directly to the CEO.
Ms. Crespo has more than 20 years of practical experience in accounting and fiscal management. She has been with Ocugen considering the fact that 2019, formerly serving as Vice President, Corporate Controller and Treasurer. Ahead of signing up for the Corporation, she held financial management roles in Aerie Pharmaceuticals, Aralez Prescription drugs and Cubist Prescribed drugs wherever she was responsible for economic and technical accounting and SEC reporting, such as the implementation of new accounting specifications and the accounting and reporting of complex transactions. Prior to that, Ms. Crespo was a senior manager in Ernst & Young’s audit and assurance observe.
“Jess has been an important member of the Ocugen workforce for nearly a few several years and we are pleased to identify her valuable contributions with this enlargement of her job. The Corporation has seen transformational development more than the previous yr, as we work to advance the therapies in our pipeline toward regulatory approval. Jess’ information and abilities will help us sustain that momentum,” said Dr. Shankar Musunuri, Chairman of the Board, Main Government Officer, and Co-founder of Ocugen.
Ms. Crespo retains a Bachelor of Science in Accounting from Boston College and is a Accredited General public Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a scientific-phase biopharmaceutical business centered on getting, establishing, and commercializing gene therapies to remedy blindness illnesses and developing a vaccine to help you save life from COVID-19. Our breakthrough modifier gene therapy system has the prospective to take care of several retinal conditions with a single drug — “one to quite a few,” and our novel biologic item prospect aims to offer far better therapy to sufferers with underserved illnesses such as moist age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-establishing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For extra details, remember to go to www.ocugen.com.
Cautionary Notice on Ahead-Seeking Statements
This press release contains ahead-searching statements within the which means of The Private Securities Litigation Reform Act of 1995, which are subject matter to threats and uncertainties. We could, in some conditions, use terms this kind of as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words and phrases that convey uncertainty of upcoming occasions or outcomes to identify these forward-looking statements. These statements are topic to quite a few important elements, hazards and uncertainties that may well cause true occasions or results to vary materially from our existing expectations. These and other pitfalls and uncertainties are a lot more totally described in our periodic filings with the Securities and Exchange Commission (“SEC”), which include the danger aspects described in the section entitled “Risk Factors” in the quarterly and yearly stories that we file with the SEC. Any ahead-on the lookout statements that we make in this press release talk only as of the date of this press release. Other than as needed by regulation, we believe no obligation to update ahead-looking statements contained in this press launch irrespective of whether as a outcome of new information and facts, potential occasions or otherwise, after the day of this push launch.
Head, Investor Relations & Communications
Resource website link